阿尔茨海默氏氏病的卡罗尔 找到了稳定 与新的药物管理局 批准的治疗Kisunla。 Alzheimer's patient Carole finds stability with new FDA-approved treatment Kisunla.

卡罗尔,72岁,患有早期症状性阿尔茨海默氏症,参加了Kisunla的临床试验,Kisunla是经林业发展局批准的氨基类治疗。 Carole, a 72-year-old with early symptomatic Alzheimer's, participated in a clinical trial for Kisunla, an FDA-approved amyloid-targeting therapy. 这种治疗减缓了她的记忆和思考在18个月中的下降。 The treatment slowed her memory and thinking decline over 18 months. 像Kisunla这样的早期诊断和治疗可以帮助维持认知健康,尽管它可能造成暂时的脑肿胀作为副作用。 Early diagnosis and therapy like Kisunla can help maintain cognitive health, though it may cause temporary brain swelling as a side effect. 卡罗尔认为她的早期诊断和治疗是她改善稳定性的功劳。 Carole credits her improved stability to her early diagnosis and treatment.